Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines
- PMID: 10803742
Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines
Abstract
The combined cytotoxic effects of the thymidylate synthase (TS) inhibitors 5-fluorouracil (5FU) and different antifolates were studied in seven colon cancer cell lines. Growth inhibition of the antifolates, Nolatrexed, Raltitrexed, GW1843U89, or MTA in combination with 5FU, was determined and multiple drug effect analysis showed that the drugs acted mostly additively. The only synergistic interaction was found for 5FU and Nolatrexed in the LS174T cell line. Also Raltitrexed and 5FU were slightly synergistic in WiDr/F cells grown at low folate levels, but for the other cell lines grown at high folate levels this combination was more antagonistic. GW1843U89 and 5FU were mainly additive, while 5FU and MTA showed antagonism in WiDr and additivity in LS174T. The effect of the drugs at their target was evaluated by in situ TS inhibition. We observed lower TS activity in all cells when two drugs were used instead of one. Statistical analysis revealed that none of the values of the combinations was higher or lower than could be expected from the product of the effect of single drugs. We concluded that the effects on TS inhibition were additive for all 5FU/antifolate combinations in all cell lines. DNA strand break formation, as a result of TS inhibition, was measured by means of a fluorometric analysis of DNA unwinding. Raltitrexed-induced DNA damage was significantly increased by 5FU in WiDr cells [single agent: 67% double stranded (ds) DNA, combination: 39% ds DNA, P<0.0001]. In LS174T a trend for antagonistic effects was observed for combinations of MTA, GW1843U89, or Raltitrexed and 5FU. The combinations showed additive effects in WiDr/F cells. The overall conclusion of the three assays in each of the cell lines indicated that 5FU and antifolate combinations were predominantly additive in colon cancer cells.
Similar articles
-
Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.Cancer Chemother Pharmacol. 2006 Jan;57(2):171-9. doi: 10.1007/s00280-005-0033-4. Epub 2005 Jul 12. Cancer Chemother Pharmacol. 2006. PMID: 16010590
-
Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.Cancer Res. 1999 Nov 1;59(21):5529-35. Cancer Res. 1999. PMID: 10554030
-
Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.Cancer Res. 2001 May 1;61(9):3675-81. Cancer Res. 2001. PMID: 11325838
-
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205. doi: 10.1016/s0925-4439(02)00082-0. Biochim Biophys Acta. 2002. PMID: 12084461 Review.
-
Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.Semin Oncol. 1999 Apr;26(2 Suppl 6):42-7. Semin Oncol. 1999. PMID: 10598554 Review.
Cited by
-
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.Cancer Sci. 2010 Feb;101(2):440-7. doi: 10.1111/j.1349-7006.2009.01375.x. Epub 2009 Sep 29. Cancer Sci. 2010. PMID: 19886911 Free PMC article.
-
The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity.Front Pharmacol. 2024 Aug 21;15:1450418. doi: 10.3389/fphar.2024.1450418. eCollection 2024. Front Pharmacol. 2024. PMID: 39234107 Free PMC article.
-
Hsp90: A New Player in DNA Repair?Biomolecules. 2015 Oct 16;5(4):2589-618. doi: 10.3390/biom5042589. Biomolecules. 2015. PMID: 26501335 Free PMC article. Review.
-
Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations.Cancers (Basel). 2021 Apr 24;13(9):2061. doi: 10.3390/cancers13092061. Cancers (Basel). 2021. PMID: 33923290 Free PMC article.
-
Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.Gastric Cancer. 2013 Jul;16(3):345-54. doi: 10.1007/s10120-012-0191-0. Epub 2012 Sep 12. Gastric Cancer. 2013. PMID: 22968820 Free PMC article.